{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:29:24Z","timestamp":1780918164849,"version":"3.54.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,21]]},"DOI":"10.7759\/cureus.8737","type":"journal-article","created":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T13:01:45Z","timestamp":1592744505000},"source":"Crossref","is-referenced-by-count":5,"title":["Resolution of Treatment-Refractory Prurigo Nodularis With Dupilumab: A Case Series"],"prefix":"10.7759","author":[{"given":"Jill K","family":"Wieser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Gail","family":"Mercurio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Somers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.09.020","article-title":"A systematic review of evidence-based treatments for prurigo nodularis","volume":"80","author":"Qureshi AA","year":"2019","unstructured":"Qureshi AA, Abate LE, Yosipovitch G, Friedman AJ. A systematic review of evidence-based treatments for prurigo nodularis. J Am Acad Dermatol. 2019, 80:756-764. 10.1016\/j.jaad.2018.09.020","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran M","year":"2020","unstructured":"Deleuran M, Tha\u00e7i D, Beck LA, et al.. Dupilumab shows long-term safety and efficacy in patients with moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020, 82:377-388. 10.1016\/j.jaad.2019.07.074","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck LA","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, et al.. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014, 371:130-139. 10.1056\/NEJMoa1314768","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000517","article-title":"Effectiveness of dupilumab for the treatment of generalized prurigo nodularis phenotype of adult atopic dermatitis","volume":"31","author":"Napolitano M","year":"2020","unstructured":"Napolitano M, Fabbrocini G, Scalvenzi M, Nistic\u00f2 SP, Dastoli S, Patruno C. Effectiveness of dupilumab for the treatment of generalized prurigo nodularis phenotype of adult atopic dermatitis. Dermatitis. 2020, 31:81-84. 10.1097\/DER.0000000000000517","journal-title":"Dermatitis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000437206","article-title":"Health-related quality of life in chronic pruritus: an analysis related to disease etiology, clinical skin conditions and itch intensity","volume":"231","author":"Warlich B","year":"2015","unstructured":"Warlich B, Fritz F, Osada N, et al.. Health-related quality of life in chronic pruritus: an analysis related to disease etiology, clinical skin conditions and itch intensity. Dermatology. 2015, 231:253-259. 10.1159\/000437206","journal-title":"Dermatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13827","article-title":"Anxiety, depression and suicide in patients with prurigo nodularis","volume":"31","author":"J\u00f8rgensen KM","year":"2017","unstructured":"J\u00f8rgensen KM, Egeberg A, Gislason GH, Skov L, Thyssen JP. Anxiety, depression and suicide in patients with prurigo nodularis. J Eur Acad Dermatol Venereol. 2017, 31:e106-e107. 10.1111\/jdv.13827","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen LK","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, et al.. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017, 171:217-228.e13. 10.1016\/j.cell.2017.08.006","journal-title":"Cell"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10498.x","article-title":"Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis","volume":"165","author":"Fukushi S","year":"2011","unstructured":"Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011, 165:990-996. 10.1111\/j.1365-2133.2011.10498.x","journal-title":"Br J Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04481.x","article-title":"Prurigo as a symptom of atopic and non\u2010atopic diseases: aetiological survey in a consecutive cohort of 108 patients","volume":"27","author":"Iking A","year":"2013","unstructured":"Iking A, Grundmann S, Chatzigeorgakidis E, Phan NQ, Klein D, St\u00e4nder S. Prurigo as a symptom of atopic and non\u2010atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol. 2013, 27:550-557. 10.1111\/j.1468-3083.2012.04481.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.3912","article-title":"Dupilumab treatment for generalized prurigo nodularis","volume":"155","author":"Beck KM","year":"2019","unstructured":"Beck KM, Yang EJ, Sekhon S, Bhutani T, Liao W. Dupilumab treatment for generalized prurigo nodularis. JAMA Dermatol. 2019, 155:118-120. 10.1001\/jamadermatol.2018.3912","journal-title":"JAMA Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.3906","article-title":"Reduced itch associated with dupilumab treatment in 4 patients with prurigo nodularis","volume":"155","author":"Mollanazar NK","year":"2019","unstructured":"Mollanazar NK, Elgash M, Weaver L, Valdes-Rodriguez R, Hsu S. Reduced itch associated with dupilumab treatment in 4 patients with prurigo nodularis. JAMA Dermatol. 2019, 155:121-122. 10.1001\/jamadermatol.2018.3906","journal-title":"JAMA Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.03.016","article-title":"Recalcitrant prurigo nodularis treated successfully with dupilumab","volume":"5","author":"Rambhia PH","year":"2019","unstructured":"Rambhia PH, Levitt JO. Recalcitrant prurigo nodularis treated successfully with dupilumab. JAAD Case Rep. 2019, 5:471-473. 10.1016\/j.jdcr.2019.03.016","journal-title":"JAAD Case Rep"},{"key":"ref13","unstructured":"Study of dupilumab for the treatment of patients with prurigo nodularis, inadequately controlled on topical prescription therapies or when those therapies are not advisable (PRIME). (2020). Accessed. May 19, 2020: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04183335."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"Stander S","year":"2020","unstructured":"Stander S, Yosipovitch G, Legat FJ, et al.. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med. 2020, 382:706-716. 10.1056\/NEJMoa1908316","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/33973-resolution-of-treatment-refractory-prurigo-nodularis-with-dupilumab-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:26:47Z","timestamp":1707506807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/33973-resolution-of-treatment-refractory-prurigo-nodularis-with-dupilumab-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,21]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.8737","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,21]]}}}